Vasoactive intestinal peptide and bipolar affective illness. Evidence for an effect of lithium.
In an attempt to evaluate the role of VIP in affective disorder, measurements of lymphocyte VIP receptors, and plasma and CSF VIP levels were made in unmedicated and lithium-treated euthymic bipolars and controls. Lithium decreased plasma (P = 0.01) and CSF (P = 0.05) VIP levels and increased the affinity (decreased the KD) of the VIP lymphocyte receptor (P less than 0.01). This effect may be relevant to the psychotropic action of lithium in manic-depressive illness.
Berrettini
W H
WH
Nurnberger
J I
JI
Hotvedt
P
P
Simmons-Alling
S
S
Gershon
E S
ES
D001714:Bipolar Disorder / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008094:Lithium / Q000627:therapeutic use*; D008214:Lymphocytes / Q000378:metabolism; D011863:Radioimmunoassay; D011956:Receptors, Cell Surface / Q000378:metabolism; D018005:Receptors, Vasoactive Intestinal Peptide; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism*
D011956:Receptors, Cell Surface; D018005:Receptors, Vasoactive Intestinal Peptide; D014660:Vasoactive Intestinal Peptide; D008094:Lithium